查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566800

过敏免疫治疗市场：按类型、应用、通路分类：2024-2033 年全球机会分析与产业预测

Allergy Immunotherapy Market By Type , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 216 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年过敏免疫治疗市场规模为18亿美元，预计2033年将达49亿美元，2024年至2033年复合年增长率为10.4%。

过敏免疫疗法是一种过敏的预防性治疗，旨在减轻对特定过敏原（如屋尘螨、蜂毒和草花粉）的过敏反应的严重程度。这种治疗方法透过逐渐增加引起过敏的过敏原剂量，使免疫系统对过敏原较不敏感，从而减轻过敏症状。这种治疗方法可以长期缓解症状并减少对过敏治疗的依赖。

全球过敏免疫治疗市场的成长主要是由于过敏性鼻炎、气喘和食物过敏等过敏性疾病盛行率的惊人上升，以及患者和医疗保健提供者对过敏免疫治疗的认识不断提高。根据2011年过敏白皮书发表的研究，不同族群中过敏性鼻炎的盛行率为1%至18%，皮肤过敏为2%至10%，气喘为1%至20%。此外，越来越多的患者寻求有效且长期的过敏管理解决方案，推动了对过敏免疫疗法的需求，并为市场成长做出了重大贡献。此外，个人化医疗的不断增长趋势正在推动对客製化免疫疗法的需求，以满足个别患者的需求和特定过敏，从而推动市场成长。然而，与过敏免疫疗法相关的高成本以及对治疗副作用的日益担忧是市场的主要阻碍因素。另一方面，新兴市场不断增长的医疗保健支出正在促进获得过敏免疫疗法等先进治疗方法，预计将在预测期内为市场成长提供利润丰厚的机会。此外，免疫治疗技术的进步，例如舌下免疫治疗的市场开拓和皮下免疫治疗配方的改进，正在使治疗更加有效和容易获得，并有望为市场成长开闢新的途径。

全球过敏免疫治疗市场按类型、应用、分销管道和区域细分。依类型分为皮下免疫治疗和舌下免疫治疗。依用途分为过敏性鼻炎、气喘、食物过敏等。依分销管道划分，市场分为医院药局、零售店及网路药局。从区域来看，分析包括北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按类型划分，皮下免疫疗法（SCIT）细分市场在 2023 年占据最高市场占有率。

从应用来看，预计到 2033 年，过敏性鼻炎细分市场将呈现最高成长率。

从分销管道来看，医院药房领域预计将在预测期内受到高度关注。

按地区划分，北美预计在未来几年主导过敏免疫治疗市场。

该报告可以定制（需要单独的费用和时间表）。

  • 监管指引
  • 根据客户兴趣新增其他公司简介
  • 扩大公司简介列表
  • 赎回场景

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章过敏免疫治疗市场：依类型

  • 市场概况
  • 皮下免疫治疗
  • 舌下免疫治疗

第五章过敏免疫治疗市场：依应用分类

  • 市场概况
  • 过敏性鼻炎
  • 气喘
  • 食物过敏
  • 其他的

第六章过敏免疫治疗市场：依通路分类

  • 市场概况
  • 医院药房
  • 零售
  • 网路药房

第七章过敏免疫治疗市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国过敏免疫治疗市场
    • 加拿大过敏免疫治疗市场
    • 墨西哥过敏免疫治疗市场
  • 欧洲
    • 主要市场趋势和机会
    • 法国过敏免疫治疗市场
    • 德国过敏免疫治疗市场
    • 义大利过敏免疫治疗市场
    • 西班牙过敏免疫治疗市场
    • 英国过敏免疫治疗市场
    • 其他欧洲过敏免疫治疗市场
  • 亚太地区
    • 主要市场趋势和机会
    • 中国过敏免疫治疗市场
    • 日本过敏免疫治疗市场
    • 印度过敏免疫治疗市场
    • 韩国过敏免疫治疗市场
    • 澳洲过敏免疫治疗市场
    • 其他亚太过敏免疫治疗市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西过敏免疫治疗市场
    • 南非过敏免疫治疗市场
    • 沙乌地阿拉伯过敏免疫治疗市场
    • 其他拉丁美洲/中东/非洲过敏免疫治疗市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • Torii Pharmaceutical Co., Ltd.
  • Biomay AG
  • ALK-Abello A/S
  • Allergy Therapeutics
  • Allovate, LLC
  • HAL Allergy Group
  • Jubliant Pharma
  • Leti Pharma
  • Merck KGaA
  • Stallergenes Greer
简介目录
Product Code: A10241

The allergy immunotherapy market was valued at $1.8 billion in 2023, and is projected to reach $4.9 billion by 2033, growing at a CAGR of 10.4% from 2024 to 2033.

Allergy immunotherapy is a preventative treatment for allergies that aims to mitigate the severity of allergic reactions to specific allergens such as house dust mites, bee venom, and grass pollens. This therapy involves gradual increase in administration of doses of the allergen to which an individual is allergic, thus making the immune systems less sensitive to the allergen and reducing the symptoms of allergy. The therapy can lead to long-term relief and decreased dependence on allergy medications.

The growth of the global allergy immunotherapy market is majorly driven by alarming rise in the prevalence of allergic conditions such as allergic rhinitis, asthma, and food allergies coupled with increase in awareness about allergy immunotherapy among patients and healthcare providers. Based on a 2011 study published in the White Book on Allergy, the prevalence rate of allergic rhinitis from 1% to 18%, skin allergies from 2% to 10%, and asthma ranges from 1% to 20% in various populations. Moreover, increase in preference of patients for effective and long-term solutions to allergy management fosters the demand for allergy immunotherapy, which significantly contributes toward the growth of the market. Furthermore, increase in trend toward personalized medicine is driving the demand for tailored immunotherapy treatments that address individual patient needs and specific allergies, which fosters the market growth. However, high cost of the associated with allergy immunotherapy and increase in concerns about the side effects of the treatment act as the key deterrent factors of the market. On the contrary, increase in healthcare expenditure in emerging markets is facilitating the access to advanced treatments like allergy immunotherapy, which is expected to offer remunerative opportunities for the growth of the market during the forecast period. Moreover, advancements in immunotherapy techniques, such as the development of sublingual immunotherapy and improved formulations of subcutaneous immunotherapy, are making treatments more effective and accessible, which are expected to open new avenues for the market growth.

The global allergy immunotherapy market is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into subcutaneous immunotherapy and sublingual immunotherapy. By application, it is segregated into allergy rhinitis, asthma, food allergy, and others. Depending on distribution channel, it is fragmented into hospital pharmacies, retail, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the subcutaneous immunotherapy (SCIT) segment held the highest market share in 2023.

By application, the allergic rhinitis segment is expected to exhibit highest growth rate by 2033.

Depending on distribution channel,, the hospital pharmacies segment is anticipated to gain high prominence during the forecast period.

Region wise, North America is projected to dominate the allergy immunotherapy market in the coming years.

Competition Analysis

Competitive analysis and profiles of the major players in the global allergy immunotherapy market include Torii Pharmaceutical Co., Ltd., Biomay AG, ALK-Abello A/S, Allergy Therapeutics, Allovate, LLC, HAL Allergy Group, Jubliant Pharma, Leti Pharma, Merck KGaA, and Stallergenes Greer. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and garner a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Reimbursement Scenario

Key Market Segments

By Type

  • Subcutaneous Immunotherapy
  • Sublingual Immunotherapy

By Application

  • Allergy Rhinitis
  • Asthma
  • Food Allergy
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Torii Pharmaceutical Co., Ltd.
    • Biomay AG
    • ALK-Abello A/S
    • Allergy Therapeutics
    • Allovate, LLC
    • HAL Allergy Group
    • Jubliant Pharma
    • Leti Pharma
    • Merck KGaA
    • Stallergenes Greer

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ALLERGY IMMUNOTHERAPY MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Subcutaneous Immunotherapy
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Sublingual Immunotherapy
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: ALLERGY IMMUNOTHERAPY MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Allergy Rhinitis
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Asthma
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Food Allergy
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Others
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country

CHAPTER 6: ALLERGY IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Retail
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Pharmacies
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: ALLERGY IMMUNOTHERAPY MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Allergy Immunotherapy Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Allergy Immunotherapy Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Allergy Immunotherapy Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Allergy Immunotherapy Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. Germany Allergy Immunotherapy Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. Italy Allergy Immunotherapy Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Spain Allergy Immunotherapy Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. UK Allergy Immunotherapy Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest of Europe Allergy Immunotherapy Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Allergy Immunotherapy Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. Japan Allergy Immunotherapy Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. India Allergy Immunotherapy Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. South Korea Allergy Immunotherapy Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. Australia Allergy Immunotherapy Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Allergy Immunotherapy Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Allergy Immunotherapy Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. South Africa Allergy Immunotherapy Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. Saudi Arabia Allergy Immunotherapy Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Allergy Immunotherapy Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Torii Pharmaceutical Co., Ltd.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Biomay AG
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. ALK-Abello A/S
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Allergy Therapeutics
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Allovate, LLC
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. HAL Allergy Group
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Jubliant Pharma
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Leti Pharma
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Merck KGaA
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Stallergenes Greer
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments